RBC Capital Reaffirms $73.0000 Target On Clovis Oncology (CLVS), Reaffirms Buy Rating; Last Week Bioblast Pharma Ltd. (ORPN) Analysts

June 16, 2018 - By Marguerite Chambers

Bioblast Pharma Ltd. (NASDAQ:ORPN) Logo

Among 3 analysts covering Bio Blast Pharma (NASDAQ:ORPN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio Blast Pharma had 5 analyst reports since August 24, 2015 according to SRatingsIntel. As per Tuesday, August 25, the company rating was upgraded by Zacks. The stock of Bioblast Pharma Ltd. (NASDAQ:ORPN) earned “Buy” rating by Rodman & Renshaw on Thursday, January 28. TH Capital maintained it with “Buy” rating and $23.0 target in Wednesday, December 9 report. Roth Capital maintained the shares of ORPN in report on Monday, August 24 with “Buy” rating. The stock has “Buy” rating by Roth Capital on Wednesday, December 9. See Bioblast Pharma Ltd. (NASDAQ:ORPN) latest ratings:

RBC Capital have a $73.0000 target price per share on the stock. The target price per share would suggest a potential upside of 60.23% from Clovis Oncology (NASDAQ:CLVS)‘s last close price. This rating was revealed to clients and investors in a research report on Sunday morning.

Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has market cap of $6.69 million. It develops Trehalose 90mg/mL IV solution, a protein stabilizer and autophagy enhancer to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. It currently has negative earnings.

The stock decreased 1.48% or $0.03 during the last trading session, reaching $2. About 29,089 shares traded. Bioblast Pharma Ltd. (NASDAQ:ORPN) has declined 4.78% since June 16, 2017 and is downtrending. It has underperformed by 17.35% the S&P500. Some Historical ORPN News: ; 19/04/2018 The Tear Film and Ocular Surface Society (TFOS) Recognizes the Bioprotectant Properties of Trehalose, a Component of Thealoz® Duo,* in the Treatment of Dry Eye

Investors sentiment increased to 2 in 2018 Q1. Its up 1.67, from 0.33 in 2017Q4. It is positive, as 2 investors sold Bioblast Pharma Ltd. shares while 1 reduced holdings. 4 funds opened positions while 2 raised stakes. 335,395 shares or 11.24% less from 377,867 shares in 2017Q4 were reported. Wells Fargo Com Mn owns 1,000 shares or 0% of their US portfolio. Bridgeway Cap Mngmt Inc owns 148,811 shares. Susquehanna Group Limited Liability Partnership accumulated 0% or 34,966 shares. Blackrock Incorporated invested 0% in Bioblast Pharma Ltd. (NASDAQ:ORPN). 2,268 are held by Deutsche Financial Bank Ag. Panagora Asset Mngmt reported 0% stake. Renaissance Technology Lc holds 0% of its portfolio in Bioblast Pharma Ltd. (NASDAQ:ORPN) for 85,200 shares. White Pine Cap Ltd has invested 0% in Bioblast Pharma Ltd. (NASDAQ:ORPN).

Another recent and important Bioblast Pharma Ltd. (NASDAQ:ORPN) news was published by Benzinga.com which published an article titled: “23 Stocks Moving In Monday’s Pre-Market Session” on May 21, 2018.

Investors sentiment is 1.05 in Q1 2018. Its the same as in 2017Q4. It has no change, as 27 investors sold Clovis Oncology, Inc. shares while 65 reduced holdings. only 27 funds opened positions while 70 raised stakes. 48.28 million shares or 1.64% less from 49.09 million shares in 2017Q4 were reported. Emerald Advisers Pa reported 206,926 shares. 15,733 were reported by Mackay Shields Ltd Limited Liability Company. The California-based California Pub Employees Retirement System has invested 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS). Proshare Advsrs invested in 30,254 shares. Daiwa Securities Incorporated invested in 0% or 271 shares. Group One Trading Lp, a Illinois-based fund reported 30,782 shares. Stratos Wealth Prtn has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Century Inc has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Aqr Capital Mngmt Ltd has invested 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Gabelli Funds Lc reported 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Kbc Grp Nv stated it has 88,163 shares. 5,152 were accumulated by Prelude Capital Ltd Llc. Rock Springs Cap Limited Partnership invested in 0.52% or 231,500 shares. The Illinois-based Northern Trust Corp has invested 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS). Susquehanna Intl Gp Limited Liability Partnership holds 0.01% or 283,665 shares.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology has $134 highest and $15 lowest target. $67.94’s average target is 49.12% above currents $45.56 stock price. Clovis Oncology had 65 analyst reports since September 10, 2015 according to SRatingsIntel. As per Tuesday, July 18, the company rating was maintained by Credit Suisse. As per Monday, July 31, the company rating was maintained by Leerink Swann. As per Monday, January 23, the company rating was maintained by Stifel Nicolaus. The firm earned “Overweight” rating on Thursday, January 26 by PiperJaffray. The rating was downgraded by Chardan Capital Markets to “Sell” on Friday, February 3. Stifel Nicolaus maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Friday, February 26 with “Buy” rating. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Thursday, January 18 by Credit Suisse. On Tuesday, December 20 the stock rating was upgraded by Chardan Capital Markets to “Neutral”. The rating was maintained by Leerink Swann on Wednesday, November 15 with “Buy”. The stock has “Outperform” rating by Evercore on Thursday, February 22.

Since January 8, 2018, it had 0 insider purchases, and 6 selling transactions for $1.45 million activity. The insider SPICKSCHEN THORLEF sold $270,090. On Thursday, February 15 the insider IVERS-READ GILLIAN C sold $162,270.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on August, 1. They expect $-1.27 earnings per share, up 1.55% or $0.02 from last year’s $-1.29 per share. After $-1.54 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts -17.53% EPS growth.

The stock increased 1.18% or $0.53 during the last trading session, reaching $45.56. About 960,036 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 11.65% since June 16, 2017 and is downtrending. It has underperformed by 24.22% the S&P500. Some Historical CLVS News: 03/04/2018 – AstraZeneca PLC Lynparza is Used for Patients With Metastatic Breast Cancer; 23/03/2018 – EMA panel for conditional OK to Clovis’s ovarian cancer drug; 23/03/2018 – CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets; 08/05/2018 – LYNPARZA® (OLAPARIB) TABLETS GET EU APPROVAL FOR TREATMENT OF; 03/04/2018 – ASTRAZENECA PLC – EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA IN BRCA-MUTATED, HER2-NEGATIVE METASTATIC; 23/03/2018 – CHMP GRANTS POSITIVE OPINION FOR CLOVIS ONCOLOGY’S RUBRACA®; 10/05/2018 – Tesaro, Clovis Look to Catalyst-Rich Year to Pull Them From Rut; 08/05/2018 – AstraZeneca: EU Approves Lynparza Tablets for Relapsed Ovarian Cancer; 15/05/2018 – Redmile Group LLC Exits Position in Clovis Oncology; 08/05/2018 – ASTRAZENECA PLC AZN.L – EUROPEAN MEDICINES AGENCY (EMA) HAS APPROVED LYNPARZA (OLAPARIB) TABLETS

More recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: Seekingalpha.com which released: “Applied Materials Has Been Overly Punished – Cramer’s Lightning Round (5/29/18)” on May 30, 2018. Also Fool.com published the news titled: “Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today” on June 04, 2018. Nasdaq.com‘s news article titled: “Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in …” with publication date: June 04, 2018 was also an interesting one.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $2.39 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>